[go: up one dir, main page]

WO2024181026A1 - Composition - Google Patents

Composition Download PDF

Info

Publication number
WO2024181026A1
WO2024181026A1 PCT/JP2024/003444 JP2024003444W WO2024181026A1 WO 2024181026 A1 WO2024181026 A1 WO 2024181026A1 JP 2024003444 W JP2024003444 W JP 2024003444W WO 2024181026 A1 WO2024181026 A1 WO 2024181026A1
Authority
WO
WIPO (PCT)
Prior art keywords
green alga
alga chlamydomonas
extract
strain
chlamydomonas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/JP2024/003444
Other languages
English (en)
Japanese (ja)
Inventor
のぞみ 塩原
翔平 木下
瑞穂 土肥
賢司 町田
稔 後藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Honda Motor Co Ltd
Original Assignee
Honda Motor Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Honda Motor Co Ltd filed Critical Honda Motor Co Ltd
Priority to JP2025503688A priority Critical patent/JPWO2024181026A1/ja
Priority to CN202480014498.9A priority patent/CN120787160A/zh
Publication of WO2024181026A1 publication Critical patent/WO2024181026A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q90/00—Cosmetics or similar toiletry preparations for specific uses not provided for in other groups of this subclass

Definitions

  • the present invention relates to a composition containing the green alga Chlamydomonas or an extract of the green alga Chlamydomonas.
  • Patent document 1 describes an isolated antibody that specifically binds to human LAG-3. It also cites Chlamydomonas reinhardtii infected with a recombinant viral expression vector containing an antibody coding sequence or transformed with a recombinant plasmid expression vector as an example of a host expression system.
  • Patent Document 2 describes the Hyundai DREAMO strain (accession number FERM BP-22306) as an example of the green alga Chlamydomonas reinhardtii.
  • the present invention aims to provide a composition containing as an active ingredient the green alga Chlamydomonas reinhardtii or an extract of the green alga Chlamydomonas reinhardtii, which functions as an agonist of the progesterone receptor.
  • a composition comprising the green alga Chlamydomonas reinhardtii or an extract of the green alga Chlamydomonas reinhardtii, wherein the green alga Chlamydomonas reinhardtii or the extract of the green alga Chlamydomonas reinhardtii contains an agonist of the progesterone receptor.
  • composition according to (1) or (2) which is a drug for treating menstrual disorders, benign prostatic hyperplasia, or prostate cancer.
  • the present invention provides a composition containing as an active ingredient the green alga Chlamydomonas reinhardtii or an extract of the green alga Chlamydomonas reinhardtii, which functions as an agonist of the progesterone receptor.
  • composition of this embodiment contains the green algae Chlamydomonas reinhardtii or an extract of the green algae Chlamydomonas reinhardtii, and the green algae Chlamydomonas reinhardtii or an extract of the green algae Chlamydomonas reinhardtii contains an agonist of the progesterone receptor.
  • the green alga Chlamydomonas is not particularly limited, but examples thereof include the UTEX 90 strain and the Hyundai DREAMO strain (accession number FERM BP-22306).
  • the UTEX 90 strain is the parent strain of the Hyundai DREAMO strain.
  • the green alga Chlamydomonas is preferably a freshwater alga, which allows it to be cultivated in large quantities on land.
  • composition of this embodiment contains as an active ingredient the green alga Chlamydomonas reinhardtii or an extract of the green alga Chlamydomonas reinhardtii, which functions as an agonist of the progesterone receptor, and can therefore be used in pharmaceuticals such as those for treating menstrual disorders, benign prostatic hyperplasia, and prostate cancer.
  • the dosage form of the medicine may be either oral (internal) or parenteral (external, injection).
  • the dosage form of the pharmaceutical product is not particularly limited, but examples include solid preparations such as tablets, granules, powders, and capsules, liquid preparations such as solutions, suspensions, and emulsions, and freeze-dried preparations.
  • the pharmaceutical product can be manufactured using known methods.
  • composition of this embodiment may be applied to, for example, quasi-drugs, cosmetics, and foods.
  • composition of this embodiment is preferably for use in humans, but may also be for use in animals other than humans.
  • the method for culturing the green alga Chlamydomonas is not particularly limited, and examples include static culture, shaking culture, submerged culture, and aeration culture.
  • the green alga Chlamydomonas can be cultivated in large quantities on land by culturing it outdoors.
  • Methods for culturing the green alga Chlamydomonas outdoors are not particularly limited, but examples include a method of culturing it in an open pond using a raceway-type bioreactor, and a method of culturing it in a flat-panel photobioreactor installed outdoors.
  • the medium used to culture the green alga Chlamydomonas is not particularly limited, but examples include TAP medium, urea medium, HSM medium, BG11 medium, etc.
  • the temperature at which the green alga Chlamydomonas is cultured is not particularly limited, but is, for example, between 2°C and 38°C.
  • the light-dark cycle for culturing the green alga Chlamydomonas is not particularly limited, but for example, is a 24-hour cycle with the light period being 6 hours or more and 24 hours or less.
  • the photosynthetically active photon flux density during the light period is not particularly limited, but is, for example, 50 ⁇ mol/m 2 /s or more and 2000 ⁇ mol/m 2 /s or less.
  • the amount of gas aeration per unit volume when culturing the green alga Chlamydomonas using the aeration culture method is not particularly limited, but is, for example, 0.001 VVM or more and 10 VVM or less. Note that VVM indicates how many times the volume of gas is aerated relative to the culture medium in one minute.
  • the concentration of carbon dioxide in the gas to be aerated is not particularly limited, but is, for example, 0.1% by volume or more and 10% by volume or less.
  • the source of carbon dioxide is not particularly limited, but examples include carbon dioxide cylinders, gas discharged from factories, and concentrated carbon dioxide captured from the atmosphere by DAC (Direct Air Capture).
  • Methods for recovering the cultured green alga Chlamydomonas are not particularly limited, but include, for example, centrifugation, filtration, etc.
  • the recovered Chlamydomonas may be dried if necessary.
  • Methods for drying the green alga Chlamydomonas are not particularly limited, but examples include freeze-drying, spray-drying, hot air drying, and sun drying.
  • the extraction method used to extract the green alga Chlamydomonas is not particularly limited, but examples include ultrasonic extraction.
  • the solvent used for extraction of the green alga Chlamydomonas is not particularly limited, but examples include lower alcohols such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, and glycerin; and hydrophilic organic solvents such as dimethyl sulfoxide (DMSO). Of these, DMSO is preferred.
  • the method for recovering an extract of the green alga Chlamydomonas is not particularly limited, but examples include centrifugation and filtration.
  • the recovered extract of the green alga Chlamydomonas may be dried if necessary.
  • the method for drying the extract of the green alga Chlamydomonas is not particularly limited, but examples include freeze-drying.
  • the recovered Honda DREAMO strain was statically cultured (precultured) for 7 days using 2 L of TAP medium under the same culture conditions as the seed culture.
  • the precultured Honda DREAMO strain was aerated (main culture) for 7 days using 5 L of urea medium under the same culture conditions as those for the seed culture.
  • the aeration conditions were as follows: Gas flow rate per unit volume: 0.15 VVM Concentration of carbon dioxide in gas: 5% by volume
  • the mixture of extract and residue was then centrifuged at 3000 rpm for 5 minutes, the residue was removed, and approximately 100 mL of extract was recovered.
  • the extract was then freeze-dried to obtain 490.74 mg of Hyundai DREAMO strain extract.
  • the DMSO solution of the Honda DREAMO strain extract was centrifuged at 15,000 rpm for 5 seconds, and the supernatant was collected to obtain the sample.
  • the maximum concentration at which there was no evidence of inhibition of cell proliferation or an effect on the optical density of the sample 100 ⁇ g/mL, was determined as the sample concentration in the assay.
  • the assay of the specimen targeting the progesterone receptor was carried out at a specimen concentration of 100 ⁇ g/mL. The number of repetitions of the assay was two. The assay was outsourced to Eurofins Pharma Discovery Services, and was carried out using two different assay systems to eliminate false positives. A target molecule with an activation rate of 50% or more was determined to have an agonistic effect.
  • Table 1 shows the assay results for the samples.
  • the extract of the Honda DREAMO strain contained in the sample contains a progesterone receptor agonist, i.e., it functions as a progesterone receptor agonist.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Food Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une composition contenant de la Chlamydomonas reinhardtii ou un extrait de Chlamydomonas reinhardtii, la Chlamydomonas reinhardtii ou l'extrait de Chlamydomonas reinhardtii contenant un agoniste d'un récepteur de progestérone.
PCT/JP2024/003444 2023-03-02 2024-02-02 Composition Pending WO2024181026A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025503688A JPWO2024181026A1 (fr) 2023-03-02 2024-02-02
CN202480014498.9A CN120787160A (zh) 2023-03-02 2024-02-02 组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-031683 2023-03-02
JP2023031683 2023-03-02

Publications (1)

Publication Number Publication Date
WO2024181026A1 true WO2024181026A1 (fr) 2024-09-06

Family

ID=92590281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/003444 Pending WO2024181026A1 (fr) 2023-03-02 2024-02-02 Composition

Country Status (3)

Country Link
JP (1) JPWO2024181026A1 (fr)
CN (1) CN120787160A (fr)
WO (1) WO2024181026A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07224029A (ja) * 1994-02-09 1995-08-22 Sogo Biyou Ikagaku Kenkyusho:Kk 抗酸化活性をもつカロチノイド含有エキス、その製造法及び抗酸化剤
JP2015189742A (ja) * 2014-03-28 2015-11-02 大阪瓦斯株式会社 Ｐｐａｒ活性組成物及びエネルギー生産設備
WO2017217116A1 (fr) * 2016-06-17 2017-12-21 本田技研工業株式会社 Nouvelle microalgue présentant une capacité d'agrégation
KR20210069544A (ko) * 2019-12-03 2021-06-11 한양대학교 산학협력단 미세조류로부터 기능성 오일을 추출하는 방법 및 기능성 오일을 포함하는 유화액
WO2021200451A1 (fr) * 2020-03-30 2021-10-07 本田技研工業株式会社 Procédé de production de glucose et procédé de production d'éthanol
WO2023053714A1 (fr) * 2021-09-30 2023-04-06 本田技研工業株式会社 Composition et extrait d'algue verte chlamydomonas reinhardtii
WO2023053715A1 (fr) * 2021-09-30 2023-04-06 本田技研工業株式会社 Composition et extrait de chlamydomonas reinhardtii

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07224029A (ja) * 1994-02-09 1995-08-22 Sogo Biyou Ikagaku Kenkyusho:Kk 抗酸化活性をもつカロチノイド含有エキス、その製造法及び抗酸化剤
JP2015189742A (ja) * 2014-03-28 2015-11-02 大阪瓦斯株式会社 Ｐｐａｒ活性組成物及びエネルギー生産設備
WO2017217116A1 (fr) * 2016-06-17 2017-12-21 本田技研工業株式会社 Nouvelle microalgue présentant une capacité d'agrégation
KR20210069544A (ko) * 2019-12-03 2021-06-11 한양대학교 산학협력단 미세조류로부터 기능성 오일을 추출하는 방법 및 기능성 오일을 포함하는 유화액
WO2021200451A1 (fr) * 2020-03-30 2021-10-07 本田技研工業株式会社 Procédé de production de glucose et procédé de production d'éthanol
WO2023053714A1 (fr) * 2021-09-30 2023-04-06 本田技研工業株式会社 Composition et extrait d'algue verte chlamydomonas reinhardtii
WO2023053715A1 (fr) * 2021-09-30 2023-04-06 本田技研工業株式会社 Composition et extrait de chlamydomonas reinhardtii

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EMANA. EL-FAYOUMY;SANAAM.M. SHANAB;HANANS. GABALLA;MOHAMEDA. TANTAWY;EMADA. SHALABY: "Evaluation of antioxidant and anticancer activity of crude extract and different fractions of Chlorella vulgaris axenic culture grown under various concentrations of copper ions", BMC COMPLEMENTARY MEDICINE AND THERAPIES, BIOMED CENTRAL LTD, LONDON, UK, vol. 21, no. 1, 5 February 2021 (2021-02-05), London, UK , pages 1 - 16, XP021287049, DOI: 10.1186/s12906-020-03194-x *
HOYT JACQUELINE, FREDEEN ALAN, GLOVER KATHLEEN, ENRIGHT CATHERINE, MACLAREN LESLIE: "Marine microalgae effects on endometrial expression of key molecules in pregnant dairy cows", BIOLOGY OF REPRODUCTION, NEW YORK, NY [U.A.] : ACADEM. PRESS, US, vol. 77, no. Suppl. 1, US , pages 103 - 103, XP009557029, ISSN: 0006-3363, Retrieved from the Internet <URL:https://academic.oup.com/biolreprod/article/77/Suppl_1/103/2950051> DOI: 10.1093/biolreprod/77.s1.103 *

Also Published As

Publication number Publication date
CN120787160A (zh) 2025-10-14
JPWO2024181026A1 (fr) 2024-09-06

Similar Documents

Publication Publication Date Title
McGhie et al. Anthocyanin glycosides from berry fruit are absorbed and excreted unmetabolized by both humans and rats
Wang et al. A polysaccharide from Inula japonica showing in vivo antitumor activity by interacting with TLR-4, PD-1, and VEGF
WO2023053715A1 (fr) Composition et extrait de chlamydomonas reinhardtii
AU2020103978A4 (en) Sea cucumber intestinal peptide and preparation method and use thereof
JP2016522227A (ja) 植物抽出物及び関連組成物を得るための方法
Teng et al. Biodistribution and immunomodulatory activities of a proteoglycan isolated from Ganoderma lucidum
WO2023053714A1 (fr) Composition et extrait d&#39;algue verte chlamydomonas reinhardtii
Niu et al. A polysaccharide from Glycyrrhiza uralensis attenuates myocardial fibrosis via modulating the MAPK/PI3K/AKT signaling pathway
US12186355B2 (en) Phytocomplex and selected extract of a meristematic cell line of a plant belonging to the genus melissa
Klimaszewska et al. Selective cytotoxic activity of Se-Methyl-Seleno-L-Cysteine–and Se-Polysaccharide–containing extracts from shiitake medicinal mushroom, Lentinus edodes (Agaricomycetes)
Fu et al. In vitro digestion and fermentation characteristics of Agrocybe cylindracea polysaccharides and their interaction with the gut microbiota
WO2024181026A1 (fr) Composition
Mangamuri et al. Isolation, structure elucidation and bioactivity of secondary metabolites produced by marine derived Streptomonospora arabica VSM-25
Zhang et al. Paenibacillus exopolysaccharide repairs GI inflammation by suppressing MAPK and NF-κB and restoring lipid production in Caco-2 cell line
Fan et al. Sargassum horneri fucoidan oligosaccharide: Purification, characterization, and antioxidant effects targeting the MAPK and KEAP1-NRF2 signaling pathways
Sihombing et al. Effect of guazuma ulmifolia lamk. extract on interleukin-1 and interleukin-2 levels as immunomodulatory agent candidates
JP6772318B2 (ja) 硫酸化ポリグルロン酸多糖又はその薬学的塩、その調製方法及びその使用
WO2024181024A1 (fr) Composition
WO2024181023A1 (fr) Composition
WO2024181025A1 (fr) Composition
WO2024181022A1 (fr) Composition
Guo et al. Structural characterization and immune activity evaluation of polysaccharide purified from Viola phillipica
Liu et al. Extraction, purification, structural characterization, bioactivities and application of polysaccharides from different parts of pine
KR101672026B1 (ko) 항-조류 인플루엔자 바이러스제, 및 항-조류 인플루엔자 바이러스제를 함유하는 제품
Sheikh et al. Formulation and Evaluation of Anti microbial Dusting Powder.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24763510

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2025503688

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 202480014498.9

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 202480014498.9

Country of ref document: CN